No abstract available.
Drosophila* ; Phosphotransferases*

No abstract available.
Cyclins* ; Hematologic Neoplasms* ; Phosphotransferases*

No abstract available.
Colorectal Neoplasms* ; Humans ; Phosphotransferases*

The cation-dependent galactose-specific flocculation activity of the Schizosaccharomyces pombe null mutant of lkh1⁺, the gene encoding LAMMER kinase homolog, has previously been reported by our group. Here, we show that disruption of prk1⁺, another flocculation associated regulatory kinase encoding gene, also resulted in cation-dependent galactose-specific flocculation. Deletion of prk1 increased the flocculation phenotype of the lkh1⁺ null mutant and its overexpression reversed the flocculation of cells caused by lkh1 deletion. Transcript levels of prk1⁺ were also decreased by lkh1⁺ deletion. Cumulatively, these results indicate that Lkh1 is one of the negative regulators acting upstream of Prk1, regulating non-sexual flocculation in fission yeast.
Flocculation* ; Phenotype ; Phosphotransferases* ; Schizosaccharomyces*

No abstract available.
Breast Neoplasms* ; Breast* ; Phosphotransferases*

No Abstract Available.
Phosphotransferases* ; Receptors, Cell Surface* ; Tyrosine*

No abstract available.
Animals ; Periodontal Ligament* ; Phosphotransferases* ; Rats*

Polycythemia vera (PV) was first described nearly 120 years ago. In the subsequent century, the clinical syndrome of PV, its natural history, its treatment, and many critical pathogenetic features of the disease were characterized. The discovery of the Janus-associated kinase - 2 mutation JAK2 V617F and the characterization of its role in myeloproliferative neoplasms have substantially changed the diagnostic paradigm for PV, and have potential to lead to new therapy and new pathogenetic insights.
Natural History ; Phosphotransferases ; Polycythemia ; Polycythemia Vera

Neurodegeneration with brain iron accumulation (NBIA) is a disorder characterized by various mixtures of extrapyramidal, pyramidal or psychiatric abnormalities associated with iron accumulation in the basal ganglia. The mutations in the pantothenate kinase gene (PANK2) were found in approximately two thirds of the patients with NBIA. We report three patients wtih NBIA, and two of them showed mutations in the PANK2 gene.
Basal Ganglia ; Brain ; Humans ; Iron ; Iron Metabolism Disorders ; Neuroaxonal Dystrophies ; Phosphotransferases ; Phosphotransferases (Alcohol Group Acceptor)

BACKGROUND: The role of the phosphatidylinositol-3 kinase signaling pathway in the development of acral melanoma has recently gained evidence. Phosphatase and tensin homologue (PTEN), one of the key molecules in the pathway, acts as a tumor suppressor through either an Akt-dependent or Akt-independent pathway. Akt accelerates degradation of p53. OBJECTIVE: We assessed the expression of PTEN, phospho-Akt (p-Akt), and p53 by immunohistochemistry in benign acral nevi, acral dysplastic nevi, and acral melanomas in the radial growth phase and with a vertical growth component. METHODS: Ten specimens in each group were included. Paraffin-embedded specimens were immunostained with antibodies for PTEN, p-Akt, and p53. We scored both the staining intensity and the proportion of positive cells. The final score was calculated by multiplying the intensity score by the proportion score. RESULTS: All specimens of benign acral nevi except one showed some degree of PTEN-negative cells. The numbers of p-Akt and p53-positive cells were higher in acral dysplastic nevi and melanoma than in benign nevi. P-Akt scores were 1.7, 1.8, 2.6, and 4.4, and p53 scores were 2.0, 2.1, 3.8, and 4.1 in each group. PTEN and p-Akt scores in advanced acral melanoma were higher than in the other neoplasms. CONCLUSION: The expression of PTEN was decreased and the expression of p-Akt was increased in acral melanoma, especially in advanced cases. The PTEN-induced pathway appears to affect the late stage of melanomagenesis. Altered expression of p-Akt is thought to be due to secondary changes following the loss of PTEN.
Antibodies ; Dysplastic Nevus Syndrome* ; Immunohistochemistry ; Melanoma ; Nevus* ; Phosphotransferases